Introduction
Chronic migraine (CM) is a prevalent, disabling neurological disorder. PREEMPT demonstrated efficacy & safety of onabotulinumtoxinA (BOTOX ® ) for prophylaxis of headaches in adults with CM.
Objective
Assess patients who received all 5 treatment cycles and completed PREEMPT clinical program.
Methods PREEMPT (two phase 3 studies: 24-wk, double-blind, placebo-controlled [DBPC], parallel-group phase, followed by 32-wk, open-label phase) evaluated efficacy & safety of onabotulinumtoxinA in CM (≥15 days/month with headache lasting ≥4 hr/day). Patients were randomized (1:1) to onabotulinumtoxinA (O) or placebo (P) every 12 wks for 2 cycles, followed by onabotulinumtoxinA for 3 cycles. Multiple headache symptom measures were evaluated. Results for the completer (5 cycles) subgroup of patients are reported.
Results
Of 1384 
Conclusion/relevance
This subgroup analysis demonstrated statistically & clinically meaningful improvements with onabotulinumtoxinA treatment (5 cycles) vs placebo (2 cycles)/onabotulinumtox-inA (3 cycles) for multiple headache symptom measures & suggests that at Week 56, patients treated earlier with onabotulinumtoxinA had better outcomes. Onabotulinum-toxinA is an effective, safe, well-tolerated long-term (3-5 cycles) treatment for prophylaxis of headache in adults with CM.
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